Which has preferable earnings & valuation, DVA or ALGN?

DaVita has higher revenue and earnings than Align Technology. DaVita is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DaVita $14.01B 0.80 $746.80M $12.22 14.36 Align Technology $4.14B 2.77 $410.35M $5.75 27.86

Is DVA or ALGN more profitable?

Align Technology has a net margin of 9.99% compared to DaVita's net margin of 6.05%. Align Technology's return on equity of 15.86% beat DaVita's return on equity. Company Net Margins Return on Equity Return on Assets DaVita 6.05% -217.63% 5.07% Align Technology 9.99% 15.86% 10.32%

Does the media refer more to DVA or ALGN?

In the previous week, Align Technology had 6 more articles in the media than DaVita. MarketBeat recorded 10 mentions for Align Technology and 4 mentions for DaVita. DaVita's average media sentiment score of 1.74 beat Align Technology's score of 1.00 indicating that DaVita is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DaVita 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Align Technology 8 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, DXCM or DVA?

DexCom has higher earnings, but lower revenue than DaVita. DaVita is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DexCom $4.66B 7.41 $836.30M $2.53 36.20 DaVita $14.01B 0.80 $746.80M $12.22 14.36

Is DXCM or DVA more profitable?

DexCom has a net margin of 20.12% compared to DaVita's net margin of 6.05%. DexCom's return on equity of 35.94% beat DaVita's return on equity. Company Net Margins Return on Equity Return on Assets DexCom 20.12% 35.94% 14.75% DaVita 6.05% -217.63% 5.07%

Does the media prefer DXCM or DVA?

In the previous week, DexCom had 15 more articles in the media than DaVita. MarketBeat recorded 19 mentions for DexCom and 4 mentions for DaVita. DaVita's average media sentiment score of 1.74 beat DexCom's score of 1.64 indicating that DaVita is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DexCom 18 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive DaVita 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger valuation and earnings, HQY or DVA?

DaVita has higher revenue and earnings than HealthEquity. DaVita is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HealthEquity $1.34B 6.61 $215.20M $2.67 39.58 DaVita $14.01B 0.80 $746.80M $12.22 14.36

Is HQY or DVA more profitable?

HealthEquity has a net margin of 17.25% compared to DaVita's net margin of 6.05%. HealthEquity's return on equity of 14.75% beat DaVita's return on equity. Company Net Margins Return on Equity Return on Assets HealthEquity 17.25% 14.75% 9.22% DaVita 6.05% -217.63% 5.07%

Does the media prefer HQY or DVA?

In the previous week, HealthEquity had 5 more articles in the media than DaVita. MarketBeat recorded 9 mentions for HealthEquity and 4 mentions for DaVita. DaVita's average media sentiment score of 1.74 beat HealthEquity's score of 1.60 indicating that DaVita is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HealthEquity 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive DaVita 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger valuation and earnings, DVA or MMSI?

DaVita has higher revenue and earnings than Merit Medical Systems. DaVita is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DaVita $14.01B 0.80 $746.80M $12.22 14.36 Merit Medical Systems $1.52B 3.57 $128.49M $2.42 37.43

Does the media refer more to DVA or MMSI?

In the previous week, Merit Medical Systems had 7 more articles in the media than DaVita. MarketBeat recorded 11 mentions for Merit Medical Systems and 4 mentions for DaVita. DaVita's average media sentiment score of 1.74 beat Merit Medical Systems' score of 0.98 indicating that DaVita is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DaVita 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Merit Medical Systems 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, CAH or DVA?

Cardinal Health has higher revenue and earnings than DaVita. DaVita is trading at a lower price-to-earnings ratio than Cardinal Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardinal Health $254.25B 0.21 $1.71B $7.23 31.66 DaVita $14.01B 0.80 $746.80M $12.22 14.36

Does the media favor CAH or DVA?

In the previous week, Cardinal Health had 48 more articles in the media than DaVita. MarketBeat recorded 52 mentions for Cardinal Health and 4 mentions for DaVita. DaVita's average media sentiment score of 1.74 beat Cardinal Health's score of 0.97 indicating that DaVita is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardinal Health 36 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DaVita 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

DaVita (DVA) Competitors

$175.45 +0.21 (+0.12%)

As of 01:40 PM Eastern

Compare

DVA vs. ALGN, DXCM, HQY, MMSI, and CAH

Should you buy DaVita stock or one of its competitors? DaVita's main competitors and comparable companies include Align Technology (ALGN), DexCom (DXCM), HealthEquity (HQY), Merit Medical Systems (MMSI), and Cardinal Health (CAH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does DaVita compare to Align Technology?

DaVita (NYSE:DVA) and Align Technology (NASDAQ:ALGN) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

DaVita has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market. Comparatively, Align Technology has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market.

Align Technology has a net margin of 9.99% compared to DaVita's net margin of 6.05%. Align Technology's return on equity of 15.86% beat DaVita's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DaVita	6.05%	-217.63%	5.07%
Align Technology	9.99%	15.86%	10.32%

In the previous week, Align Technology had 6 more articles in the media than DaVita. MarketBeat recorded 10 mentions for Align Technology and 4 mentions for DaVita. DaVita's average media sentiment score of 1.74 beat Align Technology's score of 1.00 indicating that DaVita is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DaVita	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Align Technology	8 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

90.1% of DaVita shares are held by institutional investors. Comparatively, 88.4% of Align Technology shares are held by institutional investors. 1.9% of DaVita shares are held by insiders. Comparatively, 0.8% of Align Technology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

DaVita has higher revenue and earnings than Align Technology. DaVita is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DaVita	$14.01B	0.80	$746.80M	$12.22	14.36
Align Technology	$4.14B	2.77	$410.35M	$5.75	27.86

DaVita currently has a consensus target price of $221.75, suggesting a potential upside of 26.39%. Align Technology has a consensus target price of $206.36, suggesting a potential upside of 28.83%. Given Align Technology's stronger consensus rating and higher probable upside, analysts clearly believe Align Technology is more favorable than DaVita.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DaVita	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Align Technology	0 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Align Technology beats DaVita on 11 of the 17 factors compared between the two stocks.

How does DaVita compare to DexCom?

DexCom (NASDAQ:DXCM) and DaVita (NYSE:DVA) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

97.8% of DexCom shares are held by institutional investors. Comparatively, 90.1% of DaVita shares are held by institutional investors. 0.3% of DexCom shares are held by company insiders. Comparatively, 1.9% of DaVita shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

DexCom has a net margin of 20.12% compared to DaVita's net margin of 6.05%. DexCom's return on equity of 35.94% beat DaVita's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	20.12%	35.94%	14.75%
DaVita	6.05%	-217.63%	5.07%

In the previous week, DexCom had 15 more articles in the media than DaVita. MarketBeat recorded 19 mentions for DexCom and 4 mentions for DaVita. DaVita's average media sentiment score of 1.74 beat DexCom's score of 1.64 indicating that DaVita is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	18 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
DaVita	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

DexCom has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market. Comparatively, DaVita has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market.

DexCom currently has a consensus target price of $88.71, indicating a potential downside of 3.15%. DaVita has a consensus target price of $221.75, indicating a potential upside of 26.39%. Given DaVita's higher possible upside, analysts plainly believe DaVita is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	1 Sell rating(s)	3 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.89
DaVita	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

DexCom has higher earnings, but lower revenue than DaVita. DaVita is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.66B	7.41	$836.30M	$2.53	36.20
DaVita	$14.01B	0.80	$746.80M	$12.22	14.36

Summary

DexCom beats DaVita on 12 of the 17 factors compared between the two stocks.

How does DaVita compare to HealthEquity?

HealthEquity (NASDAQ:HQY) and DaVita (NYSE:DVA) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

99.6% of HealthEquity shares are owned by institutional investors. Comparatively, 90.1% of DaVita shares are owned by institutional investors. 1.6% of HealthEquity shares are owned by company insiders. Comparatively, 1.9% of DaVita shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

HealthEquity has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market. Comparatively, DaVita has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market.

In the previous week, HealthEquity had 5 more articles in the media than DaVita. MarketBeat recorded 9 mentions for HealthEquity and 4 mentions for DaVita. DaVita's average media sentiment score of 1.74 beat HealthEquity's score of 1.60 indicating that DaVita is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HealthEquity	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
DaVita	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

HealthEquity has a net margin of 17.25% compared to DaVita's net margin of 6.05%. HealthEquity's return on equity of 14.75% beat DaVita's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HealthEquity	17.25%	14.75%	9.22%
DaVita	6.05%	-217.63%	5.07%

DaVita has higher revenue and earnings than HealthEquity. DaVita is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HealthEquity	$1.34B	6.61	$215.20M	$2.67	39.58
DaVita	$14.01B	0.80	$746.80M	$12.22	14.36

HealthEquity presently has a consensus target price of $110.93, suggesting a potential upside of 4.97%. DaVita has a consensus target price of $221.75, suggesting a potential upside of 26.39%. Given DaVita's higher possible upside, analysts plainly believe DaVita is more favorable than HealthEquity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HealthEquity	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
DaVita	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Summary

HealthEquity beats DaVita on 9 of the 16 factors compared between the two stocks.

How does DaVita compare to Merit Medical Systems?

DaVita (NYSE:DVA) and Merit Medical Systems (NASDAQ:MMSI) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

DaVita has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, Merit Medical Systems has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market.

In the previous week, Merit Medical Systems had 7 more articles in the media than DaVita. MarketBeat recorded 11 mentions for Merit Medical Systems and 4 mentions for DaVita. DaVita's average media sentiment score of 1.74 beat Merit Medical Systems' score of 0.98 indicating that DaVita is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DaVita	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Merit Medical Systems	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Merit Medical Systems has a net margin of 9.22% compared to DaVita's net margin of 6.05%. Merit Medical Systems' return on equity of 13.75% beat DaVita's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DaVita	6.05%	-217.63%	5.07%
Merit Medical Systems	9.22%	13.75%	8.10%

DaVita has higher revenue and earnings than Merit Medical Systems. DaVita is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DaVita	$14.01B	0.80	$746.80M	$12.22	14.36
Merit Medical Systems	$1.52B	3.57	$128.49M	$2.42	37.43

DaVita currently has a consensus price target of $221.75, suggesting a potential upside of 26.39%. Merit Medical Systems has a consensus price target of $100.00, suggesting a potential upside of 10.39%. Given DaVita's higher possible upside, equities research analysts plainly believe DaVita is more favorable than Merit Medical Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DaVita	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Merit Medical Systems	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67

90.1% of DaVita shares are held by institutional investors. Comparatively, 99.7% of Merit Medical Systems shares are held by institutional investors. 1.9% of DaVita shares are held by company insiders. Comparatively, 0.7% of Merit Medical Systems shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Merit Medical Systems beats DaVita on 9 of the 16 factors compared between the two stocks.

How does DaVita compare to Cardinal Health?

Cardinal Health (NYSE:CAH) and DaVita (NYSE:DVA) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

DaVita has a net margin of 6.05% compared to Cardinal Health's net margin of 0.67%. Cardinal Health's return on equity of -98.53% beat DaVita's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardinal Health	0.67%	-98.53%	4.69%
DaVita	6.05%	-217.63%	5.07%

Cardinal Health has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market. Comparatively, DaVita has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market.

87.2% of Cardinal Health shares are owned by institutional investors. Comparatively, 90.1% of DaVita shares are owned by institutional investors. 0.1% of Cardinal Health shares are owned by company insiders. Comparatively, 1.9% of DaVita shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Cardinal Health presently has a consensus price target of $266.56, indicating a potential upside of 16.47%. DaVita has a consensus price target of $221.75, indicating a potential upside of 26.39%. Given DaVita's higher probable upside, analysts plainly believe DaVita is more favorable than Cardinal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardinal Health	0 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.84
DaVita	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Cardinal Health has higher revenue and earnings than DaVita. DaVita is trading at a lower price-to-earnings ratio than Cardinal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardinal Health	$254.25B	0.21	$1.71B	$7.23	31.66
DaVita	$14.01B	0.80	$746.80M	$12.22	14.36

In the previous week, Cardinal Health had 48 more articles in the media than DaVita. MarketBeat recorded 52 mentions for Cardinal Health and 4 mentions for DaVita. DaVita's average media sentiment score of 1.74 beat Cardinal Health's score of 0.97 indicating that DaVita is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardinal Health	36 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DaVita	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

DaVita beats Cardinal Health on 9 of the 16 factors compared between the two stocks.

Get DaVita News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DVA vs. The Competition

Export

Metric	DaVita	Healthcare Providers & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$11.19B	$9.84B	$7.32B	$24.23B
Dividend Yield	N/A	2.54%	2.54%	3.71%
P/E Ratio	14.36	34.42	271.20	30.21
Price / Sales	0.80	4.88	598.47	23.68
Price / Cash	8.16	127.49	78.13	32.31
Price / Book	-23.24	4.03	13.45	6.78
Net Income	$746.80M	$311.06M	$3.46B	$1.07B
7 Day Performance	-2.60%	0.43%	2.10%	-0.67%
1 Month Performance	-26.06%	0.16%	5.02%	2.30%
1 Year Performance	27.53%	16.96%	27.65%	17.95%

DaVita Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DVA DaVita	4.8573 of 5 stars	$175.45 +0.1%	$221.75 +26.4%	+27.7%	$11.19B	$14.01B	14.36	78,000	Positive News
ALGN Align Technology	4.4956 of 5 stars	$171.16 -5.6%	$206.36 +20.6%	+10.7%	$12.99B	$4.03B	29.77	20,290	Positive News
DXCM DexCom	4.3307 of 5 stars	$88.76 -1.1%	$88.71 -0.1%	+10.5%	$33.87B	$4.66B	35.08	11,000
HQY HealthEquity	4.0565 of 5 stars	$102.33 -2.3%	$110.93 +8.4%	+17.1%	$8.76B	$1.31B	38.33	2,814	Positive News Upcoming Earnings
MMSI Merit Medical Systems	3.4532 of 5 stars	$89.73 -1.1%	$100.00 +11.4%	+3.3%	$5.42B	$1.52B	37.08	7,500	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:DVA) was last updated on 8/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DaVita (DVA) Competitors

DVA vs. ALGN, DXCM, HQY, MMSI, and CAH

How does DaVita compare to Align Technology?

Summary

How does DaVita compare to DexCom?

Summary

How does DaVita compare to HealthEquity?

Summary

How does DaVita compare to Merit Medical Systems?

Summary

How does DaVita compare to Cardinal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DVA vs. The Competition

DaVita Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

DaVita (DVA) Competitors

DVA vs. ALGN, DXCM, HQY, MMSI, and CAH

How does DaVita compare to Align Technology?

Which has more risk and volatility, DVA or ALGN?

Is DVA or ALGN more profitable?

Does the media refer more to DVA or ALGN?

Do institutionals and insiders hold more shares of DVA or ALGN?

Which has preferable earnings & valuation, DVA or ALGN?

Do analysts prefer DVA or ALGN?

Summary

How does DaVita compare to DexCom?

Do institutionals and insiders have more ownership in DXCM or DVA?

Is DXCM or DVA more profitable?

Does the media prefer DXCM or DVA?

Which has more volatility and risk, DXCM or DVA?

Do analysts recommend DXCM or DVA?

Which has preferable valuation and earnings, DXCM or DVA?

Summary

How does DaVita compare to HealthEquity?

Do insiders & institutionals hold more shares of HQY or DVA?

Which has more volatility & risk, HQY or DVA?

Does the media prefer HQY or DVA?

Is HQY or DVA more profitable?

Which has stronger valuation and earnings, HQY or DVA?

Do analysts recommend HQY or DVA?

Summary

How does DaVita compare to Merit Medical Systems?

Which has more volatility and risk, DVA or MMSI?

Does the media refer more to DVA or MMSI?

Is DVA or MMSI more profitable?

Which has stronger valuation and earnings, DVA or MMSI?

Do analysts recommend DVA or MMSI?

Do institutionals and insiders hold more shares of DVA or MMSI?

Summary

How does DaVita compare to Cardinal Health?

Is CAH or DVA more profitable?

Which has more risk and volatility, CAH or DVA?

Do institutionals and insiders have more ownership in CAH or DVA?

Do analysts prefer CAH or DVA?

Which has stronger valuation & earnings, CAH or DVA?

Does the media favor CAH or DVA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DVA vs. The Competition

DaVita Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools